Prolor May Seek Partner to Market Growth Hormone Product
This article is for subscribers only.
Prolor Biotech Inc., an Israeli company developing improved versions of existing medicines, may seek a partner for its growth-hormone treatment as final trials are set to begin this year, President Shai Novik said.
The company, which yesterday raised $35 million through a share offering, has enough cash to conduct late-stage studies of the product, known as hGH-CTP, in adults with growth-hormone deficiency as well as mid-stage testing in children with the ailment, Novik said yesterday in an interview near Tel Aviv.